LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Akciju saraksts・OraSure Technologies Inc

OraSure Technologies Inc

Slēgts

SektorsVeselības aprūpe

3.07 0.33

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.04

Max

3.14

Galvenie mērījumi
By Trading Economics
Ienākumi	-6.3M -22M
Pārdošana	1.2M 28M
EPS	-0.24
Peļņas marža	-80.132
Darbinieki	500
EBITDA	-1.8M -21M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-5.1M 207M
Iepriekšējā atvēršanas cena	2.74
Iepriekšējā slēgšanas cena	3.07

Ziņu noskaņojums

By Acuity

100%

333 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

N/A / 2.975 Atbalsts un pretestība

OraSure Technologies Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 23:31 UTC

Karstas akcijas

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026. g. 20. maijs 22:52 UTC

Galvenie tirgus virzītāji

Osisko Shares Fall on Planned Convertible Notes Offering

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 20. maijs 23:44 UTC

Peļņas

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026. g. 20. maijs 23:35 UTC

Tirgus saruna

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026. g. 20. maijs 23:30 UTC

Tirgus saruna

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026. g. 20. maijs 23:15 UTC

Tirgus saruna

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026. g. 20. maijs 23:14 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026. g. 20. maijs 23:02 UTC

Tirgus saruna

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 22:27 UTC

Tirgus saruna

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026. g. 20. maijs 22:14 UTC

Tirgus saruna

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026. g. 20. maijs 22:10 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026. g. 20. maijs 22:00 UTC

Peļņas

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026. g. 20. maijs 21:38 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026. g. 20. maijs 21:27 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026. g. 20. maijs 21:20 UTC

Peļņas

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026. g. 20. maijs 21:19 UTC

Peļņas

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026. g. 20. maijs 21:18 UTC

Peļņas

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026. g. 20. maijs 21:16 UTC

Peļņas

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

OraSure Technologies Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam OraSure Technologies Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 2.975Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Noskaņojums

By Acuity

333 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par OraSure Technologies Inc

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.